Niiki Pharma announced that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL. NKP-1339 is a novel transferrin targeted ruthenium based anti-cancer compound. The intracellular targets of NKP-1339 include GRP78, a key regulator of mis-folded protein processing...
Oncologist Notes "Significant Progress" In Fight Against Cancer
6/02/2011
The 24th National Cancer Survivors Day will be held on June 5th this year. "This annual event is a national recognition that we have made significant progress in the fight against cancer," said Dr. Patricia Robinson, director of Loyola University Health System's Cancer Survivorship Program...
Two Thirds Of Newly Diagnosed Cancer Patients Unable To Obtain Oncology Appointments
6/02/2011
Newly diagnosed cancer patients frequently face hurdles in obtaining an appointment for care with an oncologist, according to new research from the Perelman School of Medicine at the University of Pennnsylvania that will be presented Saturday, June 4 at the 2011 annual meeting of American Society of Clinical Oncology (Abstract #6128)...
Scientists Identify Overactive Genes In Aggressive Breast Cancers
6/02/2011
Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies...
Women With BRCA Mutations Can Take Hormone-Replacement Therapy Safely After Ovary Removal
6/02/2011
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during t...
Preliminary results of a Phase II study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's E7080 (lenvatinib [USAN]) demonstrated an Objective Response Rate (ORR) of 59% (34/58, 95% CI:45 - 71),[2] based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC)...
IMRT Cuts GI Side Effects From Prostate Cancer In Half Vs. 3D-CRT
6/01/2011
Intensity modulated radiation therapy, a newer, more precise form of radiation therapy, causes fewer gastrointestinal side effects when combined with hormone therapy than using three-dimensional radiation therapy, according to a study published in the June issue of the International Journal of Radiation Oncology-Biology-Physics, the official scientific journal of the American S...
MDxHealth SA (BSE:MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its MGMT test (Predict MDx for Brain) has demonstrated success in personalizing brain cancer treatment in a major international phase III study...
Symphogen To Present Data From The First Clinical Trial With Sym004 At ASCO
6/01/2011
Symphogen announced today that the company will present preliminary Phase 1 data evaluating the company's lead cancer compound, Sym004, at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago...
On 30 May 2011 The European Commission adopted the EMA's recommendation of 14 April 2011 revised on May 12, 2011 to lift the suspension of the marketing authorization of octagam® and octagam®10%, thus allowing both products back on the European markets...